Clinical Trial Update: Pamiparib Combined With Surufatinib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial is evaluating pamiparib combined with surufatinib as neoadjuvant therapy for unresectable ovarian cancer. The study is currently active but not …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• Pamiparib (pamiparib)
• Surufatinib (Surufatinib)

Snippet

Sponsor: Bai-Rong Xia | Conditions: Ovarian Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING